First-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in patients with multiple myeloma. ICPOEP 2015

Kristian Thidemann Andersen; Maja Hinge; Erik Kay Segel; Tina Ormstrup; Paw Holdgaard; Niels Pallisgaard; Gitte Birk Kerndrup; Torben Plesner

First-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in patients with multiple myeloma. ICPOEP 2015

Kristian Thidemann Andersen, Maja Hinge, Erik Kay Segel, Tina Ormstrup, Paw Holdgaard, Niels Pallisgaard, Gitte Birk Kerndrup, Torben Plesner

Vejle Sygehus

Research output: Contribution to conference without publisher/journal › Poster › Research › peer-review

Original language	English
Publication date	Nov 2015
Publication status	Published - Nov 2015
Event	2nd International Conference on Phase One and Early Phase Clinical Trials (ICPOEP) - Hong Kong, Hong Kong Duration: 20. Nov 2015 → 21. Nov 2015

Conference

Conference	2nd International Conference on Phase One and Early Phase Clinical Trials (ICPOEP)
Country/Territory	Hong Kong
City	Hong Kong
Period	20/11/2015 → 21/11/2015

Cite this

Andersen, K. T., Hinge, M., Segel, E. K., Ormstrup, T., Holdgaard, P., Pallisgaard, N., Kerndrup, G. B., & Plesner, T. (2015). First-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in patients with multiple myeloma. ICPOEP 2015. Poster session presented at 2nd International Conference on Phase One and Early Phase Clinical Trials (ICPOEP), Hong Kong, Hong Kong.

@conference{f9a9529dac5d4147a388aa02a6fb5aeb,

title = "First-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in patients with multiple myeloma. ICPOEP 2015",

author = "Andersen, {Kristian Thidemann} and Maja Hinge and Segel, {Erik Kay} and Tina Ormstrup and Paw Holdgaard and Niels Pallisgaard and Kerndrup, {Gitte Birk} and Torben Plesner",

year = "2015",

month = nov,

language = "English",

note = "2nd International Conference on Phase One and Early Phase Clinical Trials (ICPOEP) ; Conference date: 20-11-2015 Through 21-11-2015",

}

Andersen, KT, Hinge, M, Segel, EK, Ormstrup, T, Holdgaard, P, Pallisgaard, N, Kerndrup, GB & Plesner, T 2015, 'First-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in patients with multiple myeloma. ICPOEP 2015', 2nd International Conference on Phase One and Early Phase Clinical Trials (ICPOEP), Hong Kong, Hong Kong, 20/11/2015 - 21/11/2015.

First-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in patients with multiple myeloma. ICPOEP 2015. / Andersen, Kristian Thidemann; Hinge, Maja; Segel, Erik Kay et al.
2015. Poster session presented at 2nd International Conference on Phase One and Early Phase Clinical Trials (ICPOEP), Hong Kong, Hong Kong.

Research output: Contribution to conference without publisher/journal › Poster › Research › peer-review

TY - CONF

T1 - First-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in patients with multiple myeloma. ICPOEP 2015

AU - Andersen, Kristian Thidemann

AU - Hinge, Maja

AU - Segel, Erik Kay

AU - Ormstrup, Tina

AU - Holdgaard, Paw

AU - Pallisgaard, Niels

AU - Kerndrup, Gitte Birk

AU - Plesner, Torben

PY - 2015/11

Y1 - 2015/11

M3 - Poster

T2 - 2nd International Conference on Phase One and Early Phase Clinical Trials (ICPOEP)

Y2 - 20 November 2015 through 21 November 2015

ER -

Andersen KT, Hinge M, Segel EK, Ormstrup T, Holdgaard P, Pallisgaard N et al.. First-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in patients with multiple myeloma. ICPOEP 2015. 2015. Poster session presented at 2nd International Conference on Phase One and Early Phase Clinical Trials (ICPOEP), Hong Kong, Hong Kong.